Abstract
Overview:
Neurogenesis is the process by which neurons are created. This process is most
active during pre-natal development when neurogenesis is responsible for
populating the growing brain. Neural stem cells (NSCs) are the self-renewing,
multipotent cells that differentiate into the main phenotypes of the nervous
system. These cell types include neurons, astrocytes, and oligodendrocytes.
Neural progenitor cells (NPCs) are the progeny of stem cell division that
normally undergo a limited number of replication cycles in vivo.
The terms neuronal and neural also need to be defined. Technically speaking,
"neuronal" means "pertaining to neurons", and "neural" means "pertaining to
nerves, which are the cordlike bundles of fibers made up of neurons." Since
both terms ultimately are descriptive of neurons, the scientific community
uses the terms "neuronal" and "neural" interchangeably. The complexity of this
issue is explored from a marketing perspective within this report.
In 1992, Reynolds and Weiss were the first to isolate neural stem cells from
the striatal tissue of adult mice brain tissue, including the subventricular
zone, which is a neurogenic area. Since then, neural progenitor and stem cells
have been isolated from various areas of the adult brain, including
non-neurogenic areas like the spinal cord, and from other species, including
humans. During the development of the nervous system, neural progenitor cells
can either stay in the pool of proliferating undifferentiated cells or exit
the cell cycle and differentiate.
Over the past few years, neuronal stem and progenitor cells have become of
profound interest to the research community due to their potential to be used
in drug discovery and delivery applications, as well as for tools of neural
toxicology assessment. NSC transplantation also represents a ground-breaking
approach for treating a range of chronic neurological diseases and acute CNS
injuries, including Parkinson' s, Alzheimer' s and spinal cord injury, among
other conditions.
This market report focuses on recent advances in NSC research applications,
explores research priorities by market segment, highlights individual labs and
end-users of neuronal stem cell research products, explores the competitive
environment for NSC research products, and provides 5-year growth and trend
analysis. It provides detailed guidance for companies that wish to offer
strategically positioned NSC research products, including cells, kits, assays,
and related media and reagents.
Table of Contents
I. Background
- A. Neuronal Stem & Progenitor Cells
- B. Language Surrounding Neuronal Stem & Progenitor Cells
- C. Regulation of Neuronal Stem & Progenitor Cells
- D. Brief Product Background
II. Applications
- A. Basic Research
- 1. Developmental Biology
- 2. Adult Biology
- B. Drug Discovery Applications
- C. Drug Delivery Applications
- D. Neural Toxicology Assessment
- E. Neural Transplantation
- F. Brain Tumor Research
III. Application Priorities
- A. Overall
- 1. Cell-Based Therapies: Greatest shared priority across research
community
- 2. Standardized Neural Toxicology Assays: Deserve proportionally more
attention
- B. Breakdown of Neuronal Stem/Progenitor Cell Therapy, by Disorder
- Parkinson' s
- Brain Tumor / Glioma
- Stroke
- Spinal Cord Injury
- Alzheimer' s
- Other
- Huntington' s
- Multiple Sclerosis (MS)
- Epilepsy
- Amyotrophic Lateral Sclerosis (ALS)
- Schizophrenia
- Cerebral Palsy
- C. By Segment
- 1. Academic
- 2. Biotech
- 3. Pharma
IV. Patents
- A. Key U.S. Neuronal Stem and Progenitor Cell Patents
- B. Additional U.S. Patents
- C. Additional European Patents
V. Projected 5-Year Market Growth
- A. Scientific Publication Analysis
- 1. Neural vs. Neuronal Products
- 2. Stem vs. Progenitor Cell Products
- 3. Five-Year Growth Projections
- 4. Conclusions from Data
- B. Grant Rate Analysis
- 1. Neural vs. Neuronal Products
- 2. Stem vs. Progenitor Cell Products
- 3. Five-Year Growth Projections
- 4. Conclusions from Data
- C. Patent Analysis
- 1. Neural vs. Neuronal Products
- 2. Stem vs. Progenitor Cell Products
- 3. Five-Year Growth Projections
- 4. Conclusions from Data
VI. Competitors: Suppliers of Neuronal Stem & Progenitor Cell Products, including Products Offered
- A. Millipore, Inc.
- B. Stem Cell Technologies
- C. AlphaGenix, Inc.
- D. R&D Systems
- E. Cell Applications
- F. SA Biosciences
- G. ScienCell
- H. Neuromics
- I. Amaxa
- J. Invitrogen
- K. Sigma Aldrich
- L. Orion (no longer in existence)
VII. Specialty Pharmaceutical Companies: Neuronal Stem & Progenitor Cell Therapies
- A. Neuralstem, Inc
- B. NeuroNova AB
- C. NeuroGeneration
VIII. Breakdown of Stem Cell Research Activity by Cell Type
- Embryonic SCs
- Hematopoietic SCs
- Mesenchymal SCs
- Neural Stem & Progenitor Cells
- Umbilical Cord SCs
- Cancer SCs
- Other SCs
- Fetal SCs
IX. Potential Labs/Customers
- A. Academic Labs
- B. Private Labs
- C. Commercial Labs
- D. Government Labs
X. Product Ideas & Suggestions
- A. Product Categories
- 1. Cells & Tissue
- a. Fetal-Derived Neural Stem Cells
- b. Adult-Derived Neural Stem Cells
- c. Fetal-Derived Immortalized Neural Stem Cells
- d. Cryopreserved Embryonic Neurospheres
- e. Embryonic Stem Cell Derived Neural Progenitors
- f. Embryonic Primary Neuronal Tissue
- g. NSC Differentiated Progeny Cells
- 2. Kits
- a. Kits for Analysis of NSC Differentiated Progeny
- b. Stem Cell Functional Kits
- c. Neuronal Stem Cell Phenotyping Kits
- d. Neural Stem Cell Expansion Kits
- e. Neural Stem Cell Differentiation Kits
- f. Neural Stem Cell Blotting Kits
- 3. Media: Maintenance, Differentiation, Expansion, & Freezing Medium
- 4. Growth Factors
- 5. Markets: Markers for Neural Stem Cells & Differentiated Progeny
- 6. PCR Arrays
- 7. Nucleofection Tools
- 8. Neural Toxicity Assessment
- B. Product Suggestions
- 1. Neural Toxicity Assessment Products (an untapped niche)
- 2. Species-Specific Opportunities
- 3. Areas of Underdeveloped Competition
- 4. NSC Derived from Novel Sources
- 5. Neural Rosette Cells (R-NSCs)
